BeyondSpring (NASDAQ: BYSI)
BeyondSpring Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BeyondSpring Company Info
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.
News & Analysis
Why BeyondSpring Stock Is Soaring This Week
A lucrative partnership deal with a pharmaceutical giant in China bodes well for BeyondSpring's potential new blockbuster cancer drug.
This Biotech Stock Just Skyrocketed by 170%. Is It a Buy?
Don't be too quick to pull the trigger.
Why BeyondSpring Stock Skyrocketed Today
The biotech's experimental cancer therapy could be a game-changer.
These 2 Soaring Biotech Stocks Are Making the Nasdaq Stronger
The Nasdaq Composite is holding up better than its fellow market benchmarks.
Why BeyondSpring Is Plunging Today
The company announced the pricing of a public offering of common stock.
Valuation
Earnings Transcripts
BeyondSpring, Inc. (BYSI) Q4 2021 Earnings Call Transcript
BYSI earnings call for the period ending March 31, 2022.
BeyondSpring inc (BYSI) Q2 2021 Earnings Call Transcript
BYSI earnings call for the period ending June 30, 2021.
BeyondSpring Inc. (BYSI) Q1 2021 Earnings Call Transcript
BYSI earnings call for the period ending March 31, 2021.
BeyondSpring Inc. (BYSI) Q4 2020 Earnings Call Transcript
BYSI earnings call for the period ending March 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.